Form 4: Akoya Biosciences Director Disposes of All Stock Options Following Quanterix Merger
Insider Transaction Report
A director of Akoya Biosciences, Inc. disposed of all stock options as part of the company's merger with Quanterix Corporation, effective July 8, 2025.
Summary
- Thomas P. Schnettler, a Director of Akoya Biosciences, Inc. (AKYA), reported the disposition of all his stock options on July 8, 2025.
- The disposition occurred pursuant to an Amended and Restated Agreement and Plan of Merger dated April 28, 2025, between Quanterix Corporation, Wellfleet Merger Sub, Inc., and Akoya Biosciences, Inc.
- On July 8, 2025, Wellfleet Merger Sub, Inc. merged with and into Akoya Biosciences, Inc., with Akoya surviving as a wholly-owned subsidiary of Quanterix Corporation.
- As a result of the merger, all outstanding options to purchase Akoya common stock were accelerated.
- Options with a per share exercise price equal to or greater than the Per Share Merger Consideration were automatically terminated and cancelled for no consideration.
- Mr. Schnettler disposed of 16,860 options with an exercise price of $21.95, 30,549 options at $11.24, 56,322 options at $5.70, and 50,000 options at $2.01, totaling 153,731 options, all for no consideration.
Sentiment
Score: 4
Explanation: The document is a factual report of a completed transaction. While the merger itself is a significant strategic event, the specific outcome for the insider's options (cancellation for no consideration) is negative for the option holder.
Negatives
- The reporting person's stock options, totaling 153,731, were terminated and cancelled for no consideration as their exercise prices were equal to or greater than the Per Share Merger Consideration in the merger.
Risks
- Stock options held by insiders may be terminated for no consideration if their exercise price is at or above the merger consideration during a change of control event, leading to a loss of potential value for the option holder.
Future Outlook
The document reports a completed transaction related to a merger and does not provide forward-looking statements or guidance.
Industry Context
This filing indicates a consolidation event within the life sciences or biotechnology tools sector, where Quanterix Corporation has acquired Akoya Biosciences, Inc., reflecting ongoing strategic realignments in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Impact of Merger Agreement on Equity Compensation | The Amended and Restated Agreement and Plan of Merger resulted in the acceleration of all outstanding stock options and the termination/cancellation of options with exercise prices equal to or greater than the Per Share Merger Consideration for no consideration. | 07/08/2025 | This impacts the equity compensation structure for former Akoya Biosciences employees and directors, aligning their incentives with the new parent company, Quanterix, or concluding their equity holdings in Akoya. |
Stakeholder Impact
- Shareholders of Akoya Biosciences, Inc. are impacted by the merger, as Akoya became a wholly-owned subsidiary of Quanterix Corporation, implying a change in their investment vehicle or a cash payout.
- Employees and directors of Akoya Biosciences, Inc. holding stock options, such as the reporting person, were impacted by the acceleration and subsequent termination of out-of-the-money options for no consideration.
Key Dates
| Date | Description |
|---|---|
| 04/28/2025 | Date of the Amended and Restated Agreement and Plan of Merger. |
| 07/08/2025 | Closing Date of the merger between Akoya Biosciences, Inc. and Quanterix Corporation; also the transaction date for the disposition of stock options. |
| 07/10/2025 | Signature date of the reporting person for the Form 4 filing. |
| 05/21/2031 | Original expiration date of 16,860 stock options with an exercise price of $21.95. |
| 06/01/2032 | Original expiration date of 30,549 stock options with an exercise price of $11.24. |
| 06/01/2033 | Original expiration date of 56,322 stock options with an exercise price of $5.70. |
| 06/01/2034 | Original expiration date of 50,000 stock options with an exercise price of $2.01. |
Keywords
Akoya Biosciences, Quanterix, Merger, Stock Options, Insider Transaction, Form 4, Acquisition, Corporate Governance, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.